Aptahem AB (publ) (APTA.ST)
SEK 1.14
(-0.87%)
SEK 1.14
(-0.87%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -10.1 Million SEK | -10.58% |
| 2022 | -9.13 Million SEK | 67.99% |
| 2021 | -28.54 Million SEK | -17.59% |
| 2020 | -24.27 Million SEK | -38.74% |
| 2019 | -17.49 Million SEK | 15.04% |
| 2018 | -20.59 Million SEK | -101.53% |
| 2017 | -10.21 Million SEK | -4.95% |
| 2016 | -9.73 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.63 Million SEK | -4.28% |
| 2024 Q1 | -2.52 Million SEK | 23.98% |
| 2023 FY | -10.1 Million SEK | -10.58% |
| 2023 Q2 | -2.76 Million SEK | -13.63% |
| 2023 Q3 | -1.58 Million SEK | 42.92% |
| 2023 Q4 | -3.32 Million SEK | -110.13% |
| 2023 Q1 | -2.43 Million SEK | 20.34% |
| 2022 Q2 | -2.13 Million SEK | -10.98% |
| 2022 FY | -9.13 Million SEK | 67.99% |
| 2022 Q4 | -3.05 Million SEK | -50.94% |
| 2022 Q3 | -2.02 Million SEK | 4.97% |
| 2022 Q1 | -1.92 Million SEK | 69.49% |
| 2021 Q3 | -5.19 Million SEK | -9.37% |
| 2021 FY | -28.54 Million SEK | -17.59% |
| 2021 Q2 | -4.74 Million SEK | 0.0% |
| 2021 Q4 | -6.29 Million SEK | -21.22% |
| 2020 FY | -24.27 Million SEK | -38.74% |
| 2019 FY | -17.49 Million SEK | 15.04% |
| 2018 FY | -20.59 Million SEK | -101.53% |
| 2017 FY | -10.21 Million SEK | -4.95% |
| 2016 FY | -9.73 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 95.942% |
| Ziccum AB (publ) | -21.56 Million SEK | 53.132% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 38.389% |
| BioArctic AB (publ) | 252.64 Million SEK | 104.0% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -1095.83% |
| Mendus AB (publ) | -100.65 Million SEK | 89.96% |
| Genovis AB (publ.) | 54.22 Million SEK | 118.635% |
| Intervacc AB (publ) | -93.57 Million SEK | 89.202% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | 34.858% |
| Active Biotech AB (publ) | -46.48 Million SEK | 78.262% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 156.11% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 81.766% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 96.857% |
| Kancera AB (publ) | -65.04 Million SEK | 84.464% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 92.494% |
| Fluicell AB (publ) | -26.87 Million SEK | 62.406% |
| Saniona AB (publ) | -81.06 Million SEK | 87.535% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | 18.319% |
| Biovica International AB (publ) | -126.07 Million SEK | 91.985% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 76.227% |
| AcouSort AB (publ) | -17.48 Million SEK | 42.216% |
| Xintela AB (publ) | -57.23 Million SEK | 82.346% |
| Abliva AB (publ) | -96.54 Million SEK | 89.534% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 96.889% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -188.296% |
| OncoZenge AB (publ) | -15.9 Million SEK | 36.456% |
| Amniotics AB (publ) | -29.07 Million SEK | 65.243% |
| 2cureX AB (publ) | -36.36 Million SEK | 72.211% |
| CombiGene AB (publ) | -36.3 Million SEK | 72.167% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | 30.978% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 97.371% |
| Camurus AB (publ) | 532.35 Million SEK | 101.898% |
| Corline Biomedical AB | -1.78 Million SEK | -465.143% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 94.41% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 75.758% |
| I-Tech AB | 24.43 Million SEK | 141.354% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 98.718% |
| Cyxone AB (publ) | -21.66 Million SEK | 53.35% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 90.464% |
| Biosergen AB | -27.26 Million SEK | 62.939% |
| Cantargia AB (publ) | -290.01 Million SEK | 96.516% |
| NextCell Pharma AB | -43.17 Million SEK | 76.594% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 94.41% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 40.895% |
| Nanologica AB (publ) | -69.96 Million SEK | 85.557% |
| SynAct Pharma AB | -224.49 Million SEK | 95.499% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 77.126% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 57.816% |
| LIDDS AB (publ) | -40.67 Million SEK | 75.157% |
| Lipum AB (publ) | -37.25 Million SEK | 72.876% |
| BioInvent International AB (publ) | -369.94 Million SEK | 97.269% |
| Alzinova AB (publ) | -16.52 Million SEK | 38.841% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 96.013% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -58.054% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 91.219% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 49.825% |
| Simris Alg AB (publ) | -36.63 Million SEK | 72.418% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 93.106% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 96.745% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 90.89% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | 12.634% |